Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF) (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $20.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 8.61% year-over-year to $20.9 million; the trailing twelve-month figure through Mar 2026 stood at $89.4 million (up 17.79% YoY), and the FY2025 full-year result was $91.4 million, up 34.97% from the prior year.
• Depreciation & Amortization (CF) slipped to $20.9 million in Q1 2026, from $22.6 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $23.3 million in Q2 2025 to a low of $12.9 million in Q4 2022.
• A 5-year average of $17.4 million and a median of $15.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) jumped 58.41% in 2025 and dropped 8.61% in 2026, its largest moves.
• Tracing ANIP's Depreciation & Amortization (CF) over 5 years: stood at $12.9 million in 2022, then advanced by 17.87% to $15.2 million in 2023, then jumped by 48.74% to $22.6 million in 2024, then grew by 0.06% to $22.6 million in 2025, then retreated by 7.49% to $20.9 million in 2026.
• Business Quant data shows ANIP's Depreciation & Amortization (CF) at $20.9 million in Q1 2026, $22.6 million in Q4 2025, and $22.6 million in Q3 2025.